15/20/15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
14/20/14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
17/20/17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/20/17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
16/20/16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
President 59 -
Director TitleAgeSince
Director/Board Member 59 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
16/11/20 Issuer sale

Director

1,31,728 0.3818%
16/11/20 Issuer sale

Chief Financial Officer

41,038 0.1189%
16/11/20 Issuer sale

Chairman

1,36,253 0.3949%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 48Cr
+0.04%+2.67%+51.68%+100.28% 1,02700Cr
-0.09%+1.37%+52.36%+67.23% 65TCr
-0.02%+3.51%+19.54%+73.52% 47TCr
-1.22%+3.27%+37.02%+36.52% 35TCr
-0.79%+2.64%+19.18%+24.76% 27TCr
+0.58%+6.31%+9.69%+14.26% 26TCr
+1.55%+0.83%+40.38%+47.92% 21TCr
+0.79%-1.66%-23.80%-57.76% 19TCr
-0.52%+3.66%+33.72%+98.37% 19TCr
Average +0.27%+2.49%+26.64%+45.01% 40.02TCr
Weighted average by Cap. +0.19%+2.62%+35.25%+61.48%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!